December 5, 2024 02:29 PM ESTUpdated 03:51 PM

Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLC

Max Bayer

Pharma Reporter

The FDA has approved AstraZeneca’s Imfinzi to treat limited-stage small cell lung cancer, adding another lung cancer indication to one of the pharma’s best-selling drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLC

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Maze files for first biotech IPO of 2025, following $115M funding boost

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Imfinzi snags an­oth­er FDA nod to treat lung can­cer, this time for lim­it­ed-stage SCLC

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLC

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Maze files for first biotech IPO of 2025, following $115M funding boost

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering